Successful management of neonatal alloimmune thrombocytopenia in the second pregnancy: a case report

Sucesso no manejo da trombocitopenia aloimune neonatal na segunda gestação: relato de caso

Fabiana Mendes Conti¹, Sergio Hibner¹, Thiago Henrique Costa¹, Marcia Regina Dezan¹, Maria Giselda Aravechia¹, Ricardo Antonio D’Almeida Pereira¹, Andrea Tiemi Kondo¹, Elbio Antônio D’Amico², Mariza Mota¹, José Mauro Kutner¹

¹ Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
² Universidade de São Paulo, São Paulo, SP, Brazil.

Corresponding author: Fabiana Mendes Conti – Department of Hemotherapy and Cell Therapy, Hospital Israelita Albert Einstein – Avenida Albert Einstein, 627/701, 4th floor, building A – Morumbi – Zip code: 05652-900 – São Paulo, SP, Brazil – Phone: (55 11) 2151-0444 – E-mail: fabianaconti@einstein.br

Received on: Dec 12, 2012 – Accepted on: Dec 3, 2013

Financial sources: none.

DOI: 10.1590/S1679-45082014RC2729

ABSTRACT

Neonatal alloimmune thrombocytopenia is a serious disease, in which the mother produces antibodies against fetal platelet antigens inherited from the father; it is still an underdiagnosed disease. This disease is considered the platelet counterpart of the RhD hemolytic disease of the fetus and newborn, yet in neonatal alloimmune thrombocytopenia the first child is affected with fetal and/or neonatal thrombocytopenia. There is a significant risk of intracranial hemorrhage and severe neurological impairment, with a tendency for earlier and more severe thrombocytopenia in subsequent pregnancies. This article reports a case of neonatal alloimmune thrombocytopenia in the second pregnancy affected and discusses diagnosis, management and the clinical importance of this disease.

Keywords: Thrombocytopenia; Blood platelets; Thrombocytopenia, neonatal alloimmune; Infant, newborn; Case reports

INTRODUCTION

Neonatal alloimmune thrombocytopenia (NAIT) is a disease in which the mother produces antibodies against fetal platelet antigens inherited from the father and which the mother lacks. It is the platelet counterpart of the RhD hemolytic disease of the fetus and newborn. However, NAIT affects the first pregnancy and can cause intracranial hemorrhage (ICH), with a tendency for earlier and more severe thrombocytopenia in subsequent pregnancies.

We report the case of a 37-year-old woman with NAIT diagnosed in her first child and the strategy used to manage this second at-risk pregnancy.

CASE REPORT

A 37-year-old Caucasian female from São Paulo, Brazil, gave birth to a healthy male baby on February 2009 by vaginal delivery (40 weeks) weighing 3510g, Apgar 9 to 10 and no obstetric complications. In less than 24 hours of life, the newborn presented with petechiae and severe thrombocytopenia (14,000/mm³), despite normal hemoglobin and white blood cell (WBC) counts
Successful management of neonatal alloimmune thrombocytopenia in the second pregnancy

Table 1 and absence of infection. The baby was transferred to the neonatal intensive care unit (NICU) for investigation.

The platelet count reached its lowest level on day 4 (9,000/mm³), despite daily platelet transfusions and IV immunoglobulin 1g/kg. On day 8, platelets finally raised to 51,000/mm³ and the baby was discharged with 81,000/mm³ on day 9, without any bleeding complications.

Human platelet antigen (HPA) genotyping showed that the mother was HPA-1b1b, the father HPA-1a1a and the child HPA-1a1b (Figure 1). Maternal antibodies against HPA-1a were detected by monoclonal-specific antibody immobilization of platelet antigens (MAIPA), confirming the diagnosis of NAIT.

In March 2012 this patient became pregnant again. The sibling was stratified to a standard risk of bleeding and intravenous immunoglobulin (IVIG) 1g/kg/week was started at week 17. Regular ultrasound scans were performed to monitor fetal ICH. At week 20, MAIPA was performed on the mother’s serum and confirmed the anti-HPA-1a.

Non-invasive follow-up with quantitative MAIPA was used to assess the risk of neonatal thrombocytopenia instead of cordocentesis. It was performed at weeks 25, 29 and 32, and the results were 29UI/mL, 21.69UI/mL and 32.51UI/mL, respectively (Figure 2). Oral prednisone 40mg/day was started at week 32 and C-section was chosen to minimize the risk of bleeding at delivery. Moreover, HPA-1b1b donors were scheduled for plateletpheresis donation close to the estimated date of delivery.

The mother had moderate anemia during pregnancy (lowest level Hb=8.7g/dL at week 36). Hemolytic anemia due to IVIG was excluded by normal lactate dehydrogenase (LDH) levels (383mg/dL) and negative direct antiglobulin test. Since iron (87µg/dL) and ferritin (47.9g/mL) levels were normal, anemia was considered dilutional and IVIG was not interrupted.

Although delivery was scheduled for week 38, the woman went into labour and the baby was born at week 37, weighing 2750g and with Apgar 9 to 10, without petechiae or ecchymoses and a platelet count of 59,000/mm³. He remained in the neonatal ICU for close

Table 1. Hematimetric parameters of the first newborn until discharge

|       | 2/26 | 2/27 | 2/28 | 3/2 | 3/3 | 3/4 | 3/5 | 3/6 | 3/7 |
|-------|------|------|------|-----|-----|-----|-----|-----|-----|
| Erythrocytes (mm³) | 5.05 | 4.89 | 4.16 | 3.57 | 3.79 | 3.32 | 3.31 | 3.28 | 3.27 |
| Hemoglobin (g/dL) | 16.5 | 15.6 | 13.9 | 11.3 | 12.4 | 10.6 | 11.1 | 10.5 | 10.3 |
| Hematocrit (%) | 49.5 | 48.2 | 41.9 | 35.8 | 38.1 | 32.6 | 33.5 | 31.2 | 31.6 |
| MCV (fl) | 97.6 | 98.6 | 100.7 | 100.3 | 100.5 | 98.2 | 99.7 | 95.1 | 96.6 |
| MCHC (g/dL) | 33.4 | 32.3 | 33.2 | 31.7 | 32.5 | 32.5 | 33.6 | 33.8 | 32.7 |
| RDW (%) | 15.1 | 16.5 | 15.7 | 15.0 | 15.8 | 15.5 | 14.9 | 15.6 | 16.6 |
| Leucocytes (mm³) | 37,200 | 25,500 | 19,700 | 12,900 | 18,300 | 19,000 | 17,800 | 14,000 | 12,000 |
| Platelets (mm³) | 14,000 | 21,000 | 20,000 | 9,000 | 16,000 | - | 27,000 | 51,000 | 81,000 |

MCV: mean corpuscular volume; MCHC: mean corpuscular hemoglobin concentration; RDW: red cell distribution width.

Figure 1. Summary of genotyping results from mother, father and first and second child

Figure 2. Anti-HPA-1a titer curve in mother serum during second pregnancy by quantitative monoclonal-specific antibody immobilization of platelet antigens (MAIPA)
monitoring. Intracranial and abdominal ultrasound scans were normal. On day 2, he had 99,000/mm³ platelets and was discharged on day 3, asymptomatic with platelet count of 150,000/mm³. Platelet transfusions were not necessary.

**DISCUSSION**

NAIT affects 1:1000 live births, and in severe cases, evolves to ICH with severe neurological impairment in 10 to 22% of children, and 75% of bleeding occur antenatally. Despite being the most frequent cause of severe thrombocytopenia in fetuses and neonates, and the most frequent cause of ICH in the newborn, it is underdiagnosed in routine clinical practice, with only 37% of severe cases detected in the absence of antenatal screening. Antibodies against HPA-1a account for more than 80% of cases in Caucasians; anti-HPA-3a, -4a and -5a have also been reported. Mothers have the rare HPA-1b1b genotype, whereas the fetus inherit a HPA-1a allele from the father.

NAIT is suspected in a fetus with intracranial bleeding on ultrasound and neonates with bleeding or severe unexplained and/or isolated thrombocytopenia. The mother has normal platelet counts and no history of autoimmune disease or drug-induced thrombocytopenia.

Testing for fetal and neonatal alloimmune thrombocytopenia (FNAIT) should be performed in any neonate with unexplained thrombocytopenia <50,000/mm³, regardless of the presumed cause. Diagnosis is made by platelet genotyping showing HPA fetal-maternal incompatibility and detection of anti-HPA antibodies in the mother’s serum.

There is a tendency for non-invasive monitoring during pregnancy, considering that 1.3% of fetal death cases per procedure and 5.5% cases per affected pregnancy were attributed to cordocentesis. The predictive value of the quantitative MAIPA for neonatal thrombocytopenia was reported by Bertrand et al., in 2005, and results were confirmed by Killie et al., in 2008. The exact role of sequential quantitative anti-HPA measurements remains to be established, but antibody clearance along pregnancy seems to have a better prognosis.

The maternal treatment of NAIT is based on the outcome of the first affected child and is classified into: (a) standard risk: first child with platelet >20,000/mm³ and no bleeding history; (b) high risk: platelet <20,000/mm³ or neonatal bleeding; (c) very high risk: fetal bleeding between 28 and 36 weeks; and (d) extremely high risk: fetal bleeding before 28 weeks. Weekly IVIG infusions are the treatment mainstay, varying in dose (1 to 2g/kg/week) and time to start (20 weeks or earlier). High-risk mothers receive higher IVIG doses and oral prednisone 0.5-1mg/kg, starting at 16 weeks for very high risk or 12 weeks for extremely high risk pregnancies. C-section seems to be safer than vaginal delivery, especially when the fetal platelet count is unknown.

HPA-matched platelet transfusions are indicated during the first 24 hours of life if platelets <30,000/mm³ or if there are signs of bleeding. IVIG alone is not recommended, as it takes 24 to 48 hours to be effective with risk of central nervous system (CNS) bleeding. HPA-1b1b plateletpheresis donors should be contacted to donate close to the estimated date of delivery. Alternatively, the mother can donate platelets if feasible. IVIG 1g/kg for 2 days can be associated to platelet transfusions to the newborn in severe cases.

**CONCLUSION**

Neonatal alloimmune thrombocytopenia is a serious underdiagnosed condition that affects the first child associated with significant morbidity. Close monitoring during pregnancy with ultrasound scans, treatment with immunoglobulin IV and/or corticosteroids and HPA-matched platelets at delivery can provide proper medical support to this condition and reduce the incidence of neurological sequelae in the newborn.

**ACKNOWLEDGEMENTS**

We wish to thank Gerald Bertrand and Dr. Cécile Kaplan for the technical support with quantitative monoclonal-specific antibody immobilization of platelet antigens and HPA DNA control samples.

**REFERENCES**

1. Murphy MF, Bussel JB. Advances in the management of alloimmune thrombocytopenia. Br J Haematol. 2007;138(3):386-78.
2. Berkowitz RL, Bussel JB, McFarland JG. Alloimmune thrombocytopenia: state of the art 2006. Am J Obstet Gynecol. 2006;195(4):907-13.
3. Birchall JE, Murphy MF, Kaplan C, Kroll H. European Fetomaternal Alloimmune Thrombocytopenia Study Group. European collaborative study of the antenatal management of foeto-maternal alloimmune thrombocytopenia. Br J Hematol. 2003;122(2):275-88.
4. Berkowitz RL, Kolb EA, McFarland JG, Wissert M, Primiani A, Lesser ML. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol. 2006;107(1):91-8.
5. McQuilten ZK, Wood EM, Savoa H, Cole S. A review of pathophysiology and current treatment for neonatal alloimmune thrombocytopenia (NAIT) and introducing the Australian NAIT registry. Aust N Z J Obstet Gynaecol. 2011;51(3):191-9.
6. Berkowitz RL, Lesser ML, McFarland JG, Wissert M, Primiani A, Hung C, et al. Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia. Obstet Gynecol. 2007;110(2 Pt 1):249-55.
Successful management of neonatal alloimmune thrombocytopenia in the second pregnancy

7. Yinon Y, Spira M, Solomon O, Weisz B, Chayen B, Schiff E, et al. Antenatal noninvasive treatment of patients at risk for alloimmune thrombocytopenia without a history of intracranial hemorrhage. Am J Obstet Gynecol. 2006;195(4):1153-7.

8. van den Akker ES, Oepkes D, Lopriore E, Brand A, Kanhai HH. Noninvasive antenatal management of fetal and neonatal alloimmune thrombocytopenia: safe and effective. BJOG. 2007;114(4):469-73.

9. Bertrand G, Martageix C, Jallu V, Vitry F, Kaplan C. Predictive value of sequential maternal anti-HPA-1a antibody concentrations for the severity of fetal alloimmune thrombocytopenia. J Thromb Haemost. 2006;4(3):628-37.

10. Killie MK, Husebekk A, Kjeldsen-Kragh J, Skogen B. A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn. Haematologica. 2008;93(6):870-7.

11. Bertrand G, Jallu V, Gouet M, Kjaer KM, Lambin P, Husebekk A, et al. Quantification of human platelet antigen-1a antibodies with the monoclonal antibody immobilization of platelet antigens procedure. Transfusion. 2005;45(8):1319-23.

12. Bussel JB, Berkowitz RL, Hung C, Kolb EA, Wissert M, Primiani A, et al. Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus. Am J Obstet Gynecol. 2010;203(2):135.e1-14

13. Vinograd CA, Bussel JB. Antenatal treatment of fetal alloimmune thrombocytopenia: a current perspective. Haematologica. 2010;95(11):1807-11.

14. Paidas MJ. Prenatal management of neonatal alloimmune thrombocytopenia. UpToDate [Internet]. 2011. [cited 2013 Dec 2]. Available from: http://www.uptodate.com

15. Kaplan-Gouet C. Fetal and neonatal alloimmune thrombocytopenia. Orphanet [Internet]. 2003. [cited 3/11/2013]. Available from: http://http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=-853&lng=EN